Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04189783 · ClinicalTrials.gov registry record · Phase 2
Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)
A Phase 2 study of Retroperitoneal Sarcoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 1
- Study location
NCT04189783 is a Phase 2 study of Retroperitoneal Sarcoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 113 participants, below the 397-participant average among 6 other Retroperitoneal Sarcoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04189783, a Phase 2 study of Retroperitoneal Sarcoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well a repeat or single liposomal bupivacaine injection (quadratus lumborum block) works in reducing opioid prescriptions after surgery in patients with retroperitoneal sarcoma. Liposomal bupivacaine is a numbing medication. Giving a second injection block may decrease dependency on opioid medications for pain relief after surgery and prevent long-term use and addiction.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Liposomal Bupivacaine
- DRUG Quadratus Lumborum Block
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2020-06-08 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04189783
The ClinicalTrials.gov registry entry for NCT04189783 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 397-participant average among 6 other Retroperitoneal Sarcoma trials with a reported enrollment target (72% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retroperitoneal Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT04189783 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04189783 about?
NCT04189783 is a clinical study titled "Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)". This phase II trial studies how well a repeat or single liposomal bupivacaine injection (quadratus lumborum block) works in reducing opioid prescriptions after surgery in patients with retroperitoneal sarcoma. Liposomal bupivacaine is a numbing medication. Giving a second injection block may decreas...
What is the current status of trial NCT04189783?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2020-06-08. Estimated completion is 2026-12-31.
What conditions does trial NCT04189783 study?
This clinical trial studies the following conditions: Retroperitoneal Sarcoma.
What interventions are being tested in trial NCT04189783?
The interventions under investigation include: Questionnaire Administration (OTHER), Liposomal Bupivacaine (DRUG), Quadratus Lumborum Block (DRUG).
Who is sponsoring clinical trial NCT04189783?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04189783 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retroperitoneal Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma
RECRUITING · Phase 1
-
Proton or Photon RT for Retroperitoneal Sarcomas
RECRUITING · Phase 1
-
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RECRUITING · Phase 3
-
Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery
RECRUITING · Phase 1
-
REtroperitoneal SArcoma Registry: an International Prospective Initiative
RECRUITING
-
Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.